|
|
||||||||

,
,

Centre for Gene Therapeutics, Departments of
*
Pathology and Molecular Medicine and
Biology, McMaster University, Hamilton, Ontario, Canada;
Loeb Health Research Institute at the Ottawa Hospital and Faculties of Health Sciences and Medicine, University of Ottawa, Ottawa, Ontario, Canada; and
Coley Pharmaceuticals Group, Wellesley, MA 02481
Development of vaccines capable of preventing the transmission or limiting the severity of sexually transmitted viruses, such as HSV and HIV, will likely be dependent on the induction of potent long-lasting mucosal immune responses in the genital tract. Recently, synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs were shown to serve as potent adjuvants for the induction of mucosal immune responses. Here, we show that intranasal immunization with CpG ODN, plus recombinant glycoprotein B (rgB) of HSV-1, results in significantly elevated levels of specific anti-gB IgA Abs in vaginal washes that remained high throughout the estrous cycle. Additionally, dramatically elevated numbers of specific IgA Ab-secreting cells were present and persisted in the genital tract in response to intravaginal (IVAG) HSV-2 challenge. HSV-2-specific CTL were observed at moderate levels in the spleens of CpG or non-CpG ODN-immunized mice. In contrast, strong CTL responses were observed locally in the genital tissues of both groups following IVAG HSV-2 challenge. Interestingly, mice immunized intranasally with rgB plus CpG ODN, but not non-CpG ODN, were significantly protected following IVAG HSV-2 challenge. Measurement of virus in protected CpG-immunized mice revealed a log lower level of replication within the first few days after infection. In conclusion, these results indicate that intranasal immunization with CpG ODN plus protein mediates immunity in the female genital tract capable of protecting against a sexually transmitted pathogen.
This article has been cited by other articles:
![]() |
A. Kwant-Mitchell, A. A. Ashkar, and K. L. Rosenthal Mucosal Innate and Adaptive Immune Responses against Herpes Simplex Virus Type 2 in a Humanized Mouse Model J. Virol., October 15, 2009; 83(20): 10664 - 10676. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lindqvist, J. Persson, K. Thorn, and A. M. Harandi The Mucosal Adjuvant Effect of {alpha}-Galactosylceramide for Induction of Protective Immunity to Sexually Transmitted Viral Infection J. Immunol., May 15, 2009; 182(10): 6435 - 6443. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Gill and A. A. Ashkar Overexpression of Interleukin-15 Compromises CD4-Dependent Adaptive Immune Responses against Herpes Simplex Virus 2 J. Virol., January 15, 2009; 83(2): 918 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Suzuki, Y. Suzuki, I. Narita, M. Aizawa, M. Kihara, T. Yamanaka, T. Kanou, H. Tsukaguchi, J. Novak, S. Horikoshi, et al. Toll-Like Receptor 9 Affects Severity of IgA Nephropathy J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2384 - 2395. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Revaz, A. Debonneville, M. Bobst, and D. Nardelli-Haefliger Monitoring of Vaccine-Specific Gamma Interferon Induction in Genital Mucosa of Mice by Real-Time Reverse Transcription-PCR Clin. Vaccine Immunol., May 1, 2008; 15(5): 757 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Mapletoft, M. Oumouna, J. Kovacs-Nolan, L. Latimer, G. Mutwiri, L. A. Babiuk, and S. van Drunen Littel-van den Hurk Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection J. Gen. Virol., January 1, 2008; 89(1): 250 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. A. Ivory and K. Chadee Intranasal Immunization with Gal-Inhibitable Lectin plus an Adjuvant of CpG Oligodeoxynucleotides Protects against Entamoeba histolytica Challenge Infect. Immun., October 1, 2007; 75(10): 4917 - 4922. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Bae, Y.-J. Park, J.-B. Park, Y. S. Choi, M. S. Kim, and J.-I. Sin Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy Clin. Cancer Res., January 1, 2007; 13(1): 341 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Belyakov, D. Isakov, Q. Zhu, A. Dzutsev, D. Klinman, and J. A. Berzofsky Enhancement of CD8+ T Cell Immunity in the Lung by CpG Oligodeoxynucleotides Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine against Lethal Poxvirus Infection Even in a CD4-Deficient Host J. Immunol., November 1, 2006; 177(9): 6336 - 6343. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. J. Carr, L. Tomanek, R. H. Silverman, I. L. Campbell, and B. R. G. Williams RNA-Dependent Protein Kinase Is Required for Alpha-1 Interferon Transgene-Induced Resistance to Genital Herpes Simplex Virus Type 2 J. Virol., July 15, 2005; 79(14): 9341 - 9345. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. N. Toka and B. T. Rouse Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity J. Leukoc. Biol., July 1, 2005; 78(1): 178 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Buonaguro, M. L. Visciano, M. L. Tornesello, M. Tagliamonte, B. Biryahwaho, and F. M. Buonaguro Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation J. Virol., June 1, 2005; 79(11): 7059 - 7067. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Gillgrass, V. A. Tang, K. M. Towarnicki, K. L. Rosenthal, and C. Kaushic Protection against Genital Herpes Infection in Mice Immunized under Different Hormonal Conditions Correlates with Induction of Vagina-Associated Lymphoid Tissue J. Virol., March 1, 2005; 79(5): 3117 - 3126. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Q. Jiang, A. Patrick, R. B. Moss, and K. L. Rosenthal CD8+ T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG Oligodeoxynucleotides J. Virol., January 1, 2005; 79(1): 393 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-M. Kang, L. Guo, Q. Yao, I. Skountzou, and R. W. Compans Intranasal Immunization with Inactivated Influenza Virus Enhances Immune Responses to Coadministered Simian-Human Immunodeficiency Virus-Like Particle Antigens J. Virol., September 15, 2004; 78(18): 9624 - 9632. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Aurelian Herpes Simplex Virus Type 2 Vaccines: New Ground for Optimism? Clin. Vaccine Immunol., May 1, 2004; 11(3): 437 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Garulli, Y. Kawaoka, and M. R. Castrucci Mucosal and Systemic Immune Responses to a Human Immunodeficiency Virus Type 1 Epitope Induced upon Vaginal Infection with a Recombinant Influenza A Virus J. Virol., January 15, 2004; 78(2): 1020 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Prince, J. J. Mond, D. D. Porter, K. C. Yim, S. J. Lan, and D. M. Klinman Immunoprotective Activity and Safety of a Respiratory Syncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with a CpG Oligodeoxynucleotide Adjuvant J. Virol., December 15, 2003; 77(24): 13156 - 13160. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. N. Toka, M. Gierynska, and B. T. Rouse Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1 J. Virol., December 1, 2003; 77(23): 12742 - 12752. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Ashkar, S. Bauer, W. J. Mitchell, J. Vieira, and K. L. Rosenthal Local Delivery of CpG Oligodeoxynucleotides Induces Rapid Changes in the Genital Mucosa and Inhibits Replication, but Not Entry, of Herpes Simplex Virus Type 2 J. Virol., August 15, 2003; 77(16): 8948 - 8956. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kaushic, A. A. Ashkar, L. A. Reid, and K. L. Rosenthal Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection J. Virol., April 15, 2003; 77(8): 4558 - 4565. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-M. Kang and R. W. Compans Enhancement of Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus J. Virol., March 15, 2003; 77(6): 3615 - 3623. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Koelle and L. Corey Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research Clin. Microbiol. Rev., January 1, 2003; 16(1): 96 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jiang, H. J. Baker, and B. F. Smith Mucosal Immunization with Helicobacter, CpG DNA, and Cholera Toxin Is Protective Infect. Immun., January 1, 2003; 71(1): 40 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-Y. Kim, H.-J. Myoung, J.-H. Kim, I.-S. Moon, T.-G. Kim, W.-S. Ahn, and J.-I. Sin Both E7 and CpG-Oligodeoxynucleotide Are Required for Protective Immunity against Challenge with Human Papillomavirus 16 (E6/E7) Immortalized Tumor Cells: Involvement of CD4+ and CD8+ T Cells in Protection Cancer Res., December 15, 2002; 62(24): 7234 - 7240. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Csencsits and D. W. Pascual Absence of L-Selectin Delays Mucosal B Cell Responses in Nonintestinal Effector Tissues J. Immunol., November 15, 2002; 169(10): 5649 - 5659. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Pyles, D. Higgins, C. Chalk, A. Zalar, J. Eiden, C. Brown, G. Van Nest, and L. R. Stanberry Use of Immunostimulatory Sequence-Containing Oligonucleotides as Topical Therapy for Genital Herpes Simplex Virus Type 2 Infection J. Virol., October 11, 2002; 76(22): 11387 - 11396. [Abstract] [Full Text] [PDF] |
||||
![]() |
M R Wills, A J Carmichael, and J G P Sissons Vaccines against persistent DNA virus infections Br. Med. Bull., July 1, 2002; 62(1): 125 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Kline, K. Kitagaki, T. R. Businga, and V. V. Jain Treatment of established asthma in a murine model using CpG oligodeoxynucleotides Am J Physiol Lung Cell Mol Physiol, July 1, 2002; 283(1): L170 - L179. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gierynska, U. Kumaraguru, S.-K. Eo, S. Lee, A. Krieg, and B. T. Rouse Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes J. Virol., June 5, 2002; 76(13): 6568 - 6576. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |